Verition Fund Management’s PMV Pharmaceuticals PMVP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-200,938
Closed -$342K 3205
2024
Q1
$342K Sell
200,938
-1,379,549
-87% -$2.58M ﹤0.01% 2222
2023
Q4
$4.9M Sell
1,580,487
-885,901
-36% -$2.34M 0.04% 453
2023
Q3
$15.1M Buy
2,466,388
+102,192
+4% +$703K 0.18% 134
2023
Q2
$14.8M Buy
2,364,196
+216,845
+10% +$1.14M 0.2% 125
2023
Q1
$10.2M Buy
2,147,351
+1,376,092
+178% +$9.68M 0.14% 193
2022
Q4
$6.71M Buy
771,259
+627,113
+435% +$6.68M 0.1% 239
2022
Q3
$1.72M Buy
144,146
+94,678
+191% +$1.37M 0.02% 1014
2022
Q2
$705K Buy
+49,468
New +$720K 0.01% 1226

Other funds holding PMVP

Verition Fund Management's PMVP Position: Q2 2024 in Review

Verition Fund Management sold out of PMV Pharmaceuticals (PMVP) in Q2 2024, closing a stake of 200,938 shares — an estimated $342K sold.

Verition Fund Management first reported a position in PMVP in Q2 2022 and held it in 8 quarters. The position peaked at $15.1M in Q3 2023. 93 funds tracked by Wall St. Rank hold PMVP as of Q2 2024.

  • Verition Fund Management reported no remaining PMV Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Verition Fund Management sold 200,938 PMV Pharmaceuticals shares in Q2 2024, an estimated $342K.
  • Verition Fund Management first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Verition Fund Management's PMV Pharmaceuticals position peaked at $15.1M in Q3 2023.
  • 93 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2024.

Based on Verition Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.